30027497|t|The effect of NAD-299 and TCB-2 on learning and memory, hippocampal BDNF levels and amyloid plaques in Streptozotocin-induced memory deficits in male rats.
30027497|a|RATIONALE: Alzheimer's disease (AD) is the most common form of dementia characterized by a progressive decline in cognitive function. The serotonergic system via the 5-HT1A receptor and 5-HT2A receptor is proposed to affect the cognitive process. OBJECTIVE: In the present study, the effects of NAD-299 (5-HT1AR antagonist) and TCB-2 (5-HT2AR agonist) on learning and memory processes, hippocampal brain-derived neurotrophic factor (BDNF) levels, neuronal necrosis, and Abeta plaque production have been investigated on the intracerebroventricular (icv) injection of streptozotocin (STZ)-induced memory deficits in rats. METHODS: Fifty-four adult male Wistar rats (250-300 g) were divided into six groups (n = 9 in each group): control, sham-operated, AD (icv-STZ (3 mg/kg, 10 mul)), AD+NAD-299 (5 mug/1 mul icv for 30 days), AD+TCB-2 (5 mug/1 mul icv for 30 days), and AD+NAD-299 + TCB-2 (NAD-299 (5 mug/0.5 mul icv) and TCB-2 (5 mug/0.5 mul icv) for 30 days). Following the treatment period, rats were subjected to behavioral tests of learning and memory. Then, hippocampal BDNF, amyloid-beta (Abeta) plaque, and neuronal loss were determined by ELISA Kit, Congo red staining, and Nissl staining, respectively. RESULTS: The results of behavioral tests showed that icv-STZ injection decreased the discrimination index in the novel object recognition (NOR) test. In the passive avoidance learning (PAL) task, icv-STZ injection significantly decreased step-through latency (STLr) and increased time spent in dark compartment (TDC). Treatment with NAD-299, TCB-2, and NAD-299 + TCB-2 attenuated the STZ-induced memory impairment in both NOR and PAL tasks. icv-STZ induced a decrease in hippocampal BDNF levels and increased Abeta plaques production in the brain, whereas treatment with NAD-299, TCB-2, and NAD-299 + TCB-2 reduced Abeta plaques in the brain and increased the hippocampal BDNF level. Results of Nissl staining showed that icv-STZ injection increased neuronal loss in the hippocampus, while treatment with NAD-299, TCB-2, and NAD-299 + TCB-2 reduced hippocampal neurodegeneration. CONCLUSION: These findings suggest that 5-HT1AR blockade by NAD-299 and 5-HT2AR activation by TCB-2 improve cognitive dysfunction in icv-STZ-treated rats, and these drugs may potentially prevent the progression of AD.
30027497	14	21	NAD-299	Chemical	MESH:C108607
30027497	26	31	TCB-2	Chemical	-
30027497	68	72	BDNF	Gene	24225
30027497	84	99	amyloid plaques	Disease	MESH:D058225
30027497	103	117	Streptozotocin	Chemical	MESH:D013311
30027497	126	141	memory deficits	Disease	MESH:D008569
30027497	150	154	rats	Species	10116
30027497	167	186	Alzheimer's disease	Disease	MESH:D000544
30027497	188	190	AD	Disease	MESH:D000544
30027497	219	227	dementia	Disease	MESH:D003704
30027497	259	288	decline in cognitive function	Disease	MESH:D003072
30027497	451	458	NAD-299	Chemical	MESH:C108607
30027497	484	489	TCB-2	Chemical	-
30027497	554	587	brain-derived neurotrophic factor	Gene	24225
30027497	589	593	BDNF	Gene	24225
30027497	603	620	neuronal necrosis	Disease	MESH:D009336
30027497	626	631	Abeta	Gene	54226
30027497	723	737	streptozotocin	Chemical	MESH:D013311
30027497	739	742	STZ	Chemical	MESH:D013311
30027497	752	767	memory deficits	Disease	MESH:D008569
30027497	771	775	rats	Species	10116
30027497	815	819	rats	Species	10116
30027497	908	910	AD	Disease	MESH:D000544
30027497	916	919	STZ	Chemical	MESH:D013311
30027497	940	942	AD	Disease	MESH:D000544
30027497	943	950	NAD-299	Chemical	MESH:C108607
30027497	982	984	AD	Disease	MESH:D000544
30027497	985	990	TCB-2	Chemical	-
30027497	1026	1028	AD	Disease	MESH:D000544
30027497	1029	1044	NAD-299 + TCB-2	Chemical	-
30027497	1046	1053	NAD-299	Chemical	MESH:C108607
30027497	1078	1083	TCB-2	Chemical	-
30027497	1150	1154	rats	Species	10116
30027497	1232	1236	BDNF	Gene	24225
30027497	1252	1257	Abeta	Gene	54226
30027497	1271	1284	neuronal loss	Disease	MESH:D009410
30027497	1315	1324	Congo red	Chemical	MESH:D003224
30027497	1426	1429	STZ	Chemical	MESH:D013311
30027497	1569	1572	STZ	Chemical	MESH:D013311
30027497	1702	1709	NAD-299	Chemical	MESH:C108607
30027497	1711	1716	TCB-2	Chemical	-
30027497	1722	1737	NAD-299 + TCB-2	Chemical	-
30027497	1753	1756	STZ	Chemical	MESH:D013311
30027497	1765	1782	memory impairment	Disease	MESH:D008569
30027497	1814	1817	STZ	Chemical	MESH:D013311
30027497	1852	1856	BDNF	Gene	24225
30027497	1878	1883	Abeta	Gene	54226
30027497	1940	1947	NAD-299	Chemical	MESH:C108607
30027497	1949	1954	TCB-2	Chemical	-
30027497	1960	1975	NAD-299 + TCB-2	Chemical	-
30027497	1984	1989	Abeta	Gene	54226
30027497	2041	2045	BDNF	Gene	24225
30027497	2095	2098	STZ	Chemical	MESH:D013311
30027497	2119	2132	neuronal loss	Disease	MESH:D009410
30027497	2174	2181	NAD-299	Chemical	MESH:C108607
30027497	2183	2188	TCB-2	Chemical	-
30027497	2194	2209	NAD-299 + TCB-2	Chemical	-
30027497	2230	2247	neurodegeneration	Disease	MESH:D019636
30027497	2309	2316	NAD-299	Chemical	MESH:C108607
30027497	2343	2348	TCB-2	Chemical	-
30027497	2357	2378	cognitive dysfunction	Disease	MESH:D003072
30027497	2386	2389	STZ	Chemical	MESH:D013311
30027497	2398	2402	rats	Species	10116
30027497	2463	2465	AD	Disease	MESH:D000544
30027497	Positive_Correlation	MESH:D013311	MESH:D000544
30027497	Negative_Correlation	MESH:C108607	MESH:D013311
30027497	Negative_Correlation	MESH:C108607	MESH:D008569
30027497	Positive_Correlation	MESH:D013311	MESH:D008569
30027497	Negative_Correlation	MESH:C108607	MESH:D000544
30027497	Association	MESH:C108607	24225

